Influence of COVID‐19 in Patients with Concurrent Tuberculosis Coinfections
Guoying Wang,Linghao Cai,Dandan Chen,Tieshan Teng,Qiming Li,Longxiang Xie
DOI: https://doi.org/10.1002/jmv.26801
IF: 20.693
2021-01-01
Journal of Medical Virology
Abstract:Journal of Medical VirologyVolume 93, Issue 4 p. 1937-1939 LETTER TO THE EDITOR Influence of COVID-19 in patients with concurrent tuberculosis coinfections Guoying Wang, Guoying Wang Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, ChinaSearch for more papers by this authorLinghao Cai, Linghao Cai Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, ChinaSearch for more papers by this authorDandan Chen, Dandan Chen Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, ChinaSearch for more papers by this authorTieshan Teng, Corresponding Author Tieshan Teng [email protected] orcid.org/0000-0002-2150-0261 Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China Correspondence Tieshan Teng, Qiming Li, and Longxiang Xie, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China. Email: [email protected] (T. T.); [email protected] (Q. L.) and [email protected] (L. X.)Search for more papers by this authorQiming Li, Corresponding Author Qiming Li [email protected] orcid.org/0000-0002-6916-3954 Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China Correspondence Tieshan Teng, Qiming Li, and Longxiang Xie, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China. Email: [email protected] (T. T.); [email protected] (Q. L.) and [email protected] (L. X.)Search for more papers by this authorLongxiang Xie, Corresponding Author Longxiang Xie [email protected] orcid.org/0000-0001-6825-9690 Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China Correspondence Tieshan Teng, Qiming Li, and Longxiang Xie, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China. Email: [email protected] (T. T.); [email protected] (Q. L.) and [email protected] (L. X.)Search for more papers by this author Guoying Wang, Guoying Wang Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, ChinaSearch for more papers by this authorLinghao Cai, Linghao Cai Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, ChinaSearch for more papers by this authorDandan Chen, Dandan Chen Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, ChinaSearch for more papers by this authorTieshan Teng, Corresponding Author Tieshan Teng [email protected] orcid.org/0000-0002-2150-0261 Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China Correspondence Tieshan Teng, Qiming Li, and Longxiang Xie, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China. Email: [email protected] (T. T.); [email protected] (Q. L.) and [email protected] (L. X.)Search for more papers by this authorQiming Li, Corresponding Author Qiming Li [email protected] orcid.org/0000-0002-6916-3954 Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China Correspondence Tieshan Teng, Qiming Li, and Longxiang Xie, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China. Email: [email protected] (T. T.); [email protected] (Q. L.) and [email protected] (L. X.)Search for more papers by this authorLongxiang Xie, Corresponding Author Longxiang Xie [email protected] orcid.org/0000-0001-6825-9690 Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China Correspondence Tieshan Teng, Qiming Li, and Longxiang Xie, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China. Email: [email protected] (T. T.); [email protected] (Q. L.) and [email protected] (L. X.)Search for more papers by this author First published: 17 January 2021 https://doi.org/10.1002/jmv.26801Citations: 2 Guoying Wang and Linghao Cai are the cofirst authors. Funding information: China Postdoctoral Science Foundation, Grant/Award Numbers: 2020M682279; Key Scientific Research Project Plan of Henan Province, Grant/Award Numbers: 20A180001, 20A310002; Projects for College Students in Henan University, Grant/Award Numbers: 2020101901, 2020102212; Program for Science and Technology Development in Henan Province, Grant/Award Numbers: 202102310205; National Natural Science Foundation of China, Grant/Award Numbers: 82002172 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses. J Med Virol, 2020. https://doi.org/10.1002/jmv.26740 10.1002/jmv.26740 Web of Science®Google Scholar 2Higgins J, Green S. eds. Cochrane Handbook For Systematic Reviews of Interventions Version 5.1.0. (The Cochrane Collaboration, 2011); 2017. http://handbook.cochrane.org. Accessed June 19, 2017. Google Scholar 3Chen T, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci 2020; 75: 1788-1795. https://doi.org/10.1093/gerona/glaa089 10.1093/gerona/glaa089 CASPubMedWeb of Science®Google Scholar 4Davies MA. HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province, South Africa. Medrxiv. 2020. https://doi.org/10.1101/2020.07.02.20145185 Google Scholar 5Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55(5):2000524. 10.1183/13993003.00524-2020 CASPubMedWeb of Science®Google Scholar 6Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis. 2020; 52(12): 902-907. https://doi.org/10.1080/23744235 10.1080/23744235.2020.1806353 Web of Science®Google Scholar 7 CDC. COVID-19 response team severe outcomes among patients with coronavirus disease 2019 (COVID–19)–United States, Feb 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 343-346. 10.15585/mmwr.mm6912e2 PubMedWeb of Science®Google Scholar Citing Literature Volume93, Issue4Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐XIApril 2021Pages 1937-1939 ReferencesRelatedInformation